Delivery Order SPE2DB22D3016-SPE2DB25FBHV9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $1,957.32. This competitive, firm fixed-price delivery order is set to be completed by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under a larger contract vehicle, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $37,730.25. This competitively awarded, firm fixed-price delivery order is set to be completed by August 20, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials, with a ceiling value of $23,512.44. This competitively awarded, firm fixed-price delivery order is set to conclude on July 22, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a ceiling value of $16,214.41. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a contract ceiling value of $5,010.26. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) injectable medication with a ceiling value of $26,288.04. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $10,577.76 delivery order to AmerisourceBergen Drug Corp for Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with a ceiling value of $3,071.96. This is a firm fixed-price delivery order with no set-aside designation, meaning the award was competitively sourced. The contract is set to be completed by August 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) vials with a ceiling value of $3,759.96. This contract represents a firm fixed-price delivery order with no set-aside designation, utilizing open competition. The order is set for ultimate completion by August 15, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $2,819.97 and an ultimate completion date of August 18, 2025. This contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award conditions. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBHV9Delivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $2,685.52. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The contract is scheduled for completion by September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order falls within the company's extensive portfolio of federal contracts covering diabetes medications, neurological treatments, pain management pharmaceuticals, and other medical supplies. The company's capability to fulfill this order through open competition, combined with its status as a prime vendor under the DLA's comprehensive pharmaceutical contract vehicle, demonstrates its established role in supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 9/10/25 |